JP2024503021A5 - - Google Patents

Info

Publication number
JP2024503021A5
JP2024503021A5 JP2023541734A JP2023541734A JP2024503021A5 JP 2024503021 A5 JP2024503021 A5 JP 2024503021A5 JP 2023541734 A JP2023541734 A JP 2023541734A JP 2023541734 A JP2023541734 A JP 2023541734A JP 2024503021 A5 JP2024503021 A5 JP 2024503021A5
Authority
JP
Japan
Application number
JP2023541734A
Other languages
Japanese (ja)
Other versions
JP2024503021A (ja
JPWO2022150676A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011756 external-priority patent/WO2022150676A1/en
Publication of JP2024503021A publication Critical patent/JP2024503021A/ja
Publication of JP2024503021A5 publication Critical patent/JP2024503021A5/ja
Publication of JPWO2022150676A5 publication Critical patent/JPWO2022150676A5/ja
Pending legal-status Critical Current

Links

JP2023541734A 2021-01-11 2022-01-10 Jak経路阻害剤及びrock阻害剤を含む併用療法 Pending JP2024503021A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135969P 2021-01-11 2021-01-11
US63/135,969 2021-01-11
US202163253384P 2021-10-07 2021-10-07
US63/253,384 2021-10-07
PCT/US2022/011756 WO2022150676A1 (en) 2021-01-11 2022-01-10 Combination therapy comprising jak pathway inhibitor and rock inhibitor

Publications (3)

Publication Number Publication Date
JP2024503021A JP2024503021A (ja) 2024-01-24
JP2024503021A5 true JP2024503021A5 (https=) 2025-01-24
JPWO2022150676A5 JPWO2022150676A5 (https=) 2025-01-24

Family

ID=80119468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541734A Pending JP2024503021A (ja) 2021-01-11 2022-01-10 Jak経路阻害剤及びrock阻害剤を含む併用療法

Country Status (11)

Country Link
US (2) US11918581B2 (https=)
EP (1) EP4274578A1 (https=)
JP (1) JP2024503021A (https=)
KR (1) KR20230157307A (https=)
AU (1) AU2022206313A1 (https=)
CA (1) CA3207859A1 (https=)
CL (2) CL2023002004A1 (https=)
IL (1) IL304320A (https=)
MX (1) MX2023008141A (https=)
TW (1) TW202237083A (https=)
WO (1) WO2022150676A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2024153147A1 (zh) * 2023-01-18 2024-07-25 北京普祺医药科技股份有限公司 一种氮杂环烷烃化合物、药物组合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
PT868186E (pt) 1995-12-21 2005-05-31 Alcon Lab Inc Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
DE69922494T2 (de) 1998-02-04 2005-05-25 Banyu Pharmaceutical Co., Ltd. Zyklische n-acylamin-derivate
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
AU5198199A (en) 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
MXPA03008659A (es) 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
WO2005080394A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションIncyte Corporation ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
CA2880083A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
SMT201900223T1 (it) 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13157U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13149U (https=)